136 related articles for article (PubMed ID: 38582281)
1. Oral Formulation of 5-Aminosalicylic Acid-Hemoglobin Bio-Adhesive Nanoparticles Enhance Therapeutic Efficiency in Ulcerative Colitis Mice: A Preclinical Evaluation.
Vaezi Z; Baradaran Ghavami S; Farmani M; Mahdavian R; Asadzadeh Aghdaei H; Naderi-Manesh H
J Pharm Sci; 2024 Apr; ():. PubMed ID: 38582281
[TBL] [Abstract][Full Text] [Related]
2. Hemoglobin bio-adhesive nanoparticles as a colon-specific delivery system for sustained release of 5-aminosalicylic acid in the effective treatment of inflammatory bowel disease.
Vaezi Z; Asadzadeh Aghdaei H; Sedghi M; Mahdavian R; Molakarimi M; Hashemi N; Naderi-Manesh H
Int J Pharm; 2022 Mar; 616():121531. PubMed ID: 35121044
[TBL] [Abstract][Full Text] [Related]
3. Inflamed site-specific drug delivery system based on the interaction of human serum albumin nanoparticles with myeloperoxidase in a murine model of experimental colitis.
Iwao Y; Tomiguchi I; Domura A; Mantaira Y; Minami A; Suzuki T; Ikawa T; Kimura SI; Itai S
Eur J Pharm Biopharm; 2018 Apr; 125():141-147. PubMed ID: 29407223
[TBL] [Abstract][Full Text] [Related]
4. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
[TBL] [Abstract][Full Text] [Related]
6. Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis.
Ahmad A; Ansari MM; Mishra RK; Kumar A; Vyawahare A; Verma RK; Raza SS; Khan R
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 119():111582. PubMed ID: 33321628
[TBL] [Abstract][Full Text] [Related]
7. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis.
Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M
Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
9. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Wang Y; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2016 May; 2016(5):CD000544. PubMed ID: 27158764
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Li J; Chen C; Cao XN; Wang GH; Hu JB; Wang J
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):59-65. PubMed ID: 24496680
[TBL] [Abstract][Full Text] [Related]
11. 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
Tang H; Xiang D; Wang F; Mao J; Tan X; Wang Y
Mol Med Rep; 2017 Mar; 15(3):1117-1122. PubMed ID: 28138699
[TBL] [Abstract][Full Text] [Related]
12. Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-κB activation.
Zheng L; Zhang YL; Dai YC; Chen X; Chen DL; Dai YT; Tang ZP
World J Gastroenterol; 2017 Feb; 23(7):1180-1188. PubMed ID: 28275298
[TBL] [Abstract][Full Text] [Related]
13. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
[TBL] [Abstract][Full Text] [Related]
14. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000544. PubMed ID: 32856298
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis.
Yan Y; Ren F; Wang P; Sun Y; Xing J
Iran J Basic Med Sci; 2019 Dec; 22(12):1452-1461. PubMed ID: 32133064
[TBL] [Abstract][Full Text] [Related]
16. pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis.
Mahami S; Salehi M; Mehrabi M; Vahedi H; Hassani MS; Bitaraf FS; Omri A
Int J Biol Macromol; 2023 Jul; 244():125332. PubMed ID: 37302632
[TBL] [Abstract][Full Text] [Related]
17. Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon targeted delivery of 5-ASA pellets in rats with ulcerative colitis.
Shahdadi Sardou H; Akhgari A; Mohammadpour AH; Beheshti Namdar A; Kamali H; Jafarian AH; Afrasiabi Garekani H; Sadeghi F
Eur J Pharm Sci; 2022 Jan; 168():106072. PubMed ID: 34774715
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 5-ASA layered or matrix pellets coated with a combination of ethylcellulose and eudragits L and s in the treatment of ulcerative colitis in rats.
Sardou HS; Sadeghi F; Garekani HA; Akhgari A; Hossein Jafarian A; Abbaspour M; Nokhodchi A
Int J Pharm; 2023 Jun; 640():122981. PubMed ID: 37120124
[TBL] [Abstract][Full Text] [Related]
19. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats.
Tozaki H; Odoriba T; Okada N; Fujita T; Terabe A; Suzuki T; Okabe S; Muranishi S; Yamamoto A
J Control Release; 2002 Jul; 82(1):51-61. PubMed ID: 12106976
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
